银杏
生物利用度
异鼠李素
生物等效性
山奈酚
药代动力学
药理学
槲皮素
类黄酮
糖苷
医学
银杏
口服
最大值
传统医学
化学
生药学
抗氧化剂
立体化学
生物化学
生物活性
体外
作者
J Wójcicki,B Gawrońska-Szklarz,W Bieganowski,M Patalan,H K Smulski,L Samochowiec,J Zakrzewski
出处
期刊:PubMed
日期:1995-10-01
卷期号:27 (4): 141-6
被引量:9
摘要
Eighteen healthy volunteers received three different formulations of Ginkgo biloba: capsules (A) and drops (B) (delivered by Agon Pharma), and tablets (C) (Tebonin-Dr. W. Schwabe) in equal an quantity, orally as a single dose, at an interval of at least five days. The pharmacokinetic parameters of the most important flavonoid glycosides: quercetin, kaempferol and isorhamnetin were established. The bioavailability was estimated using capsules as a standard formulation. Only the time to reach the peak concentration (tmax) of quercetin, kaempforol and isorhamnetin administered in the form of capsules, was significantly prolonged as compared with drops and tablets. Area under the curve (AUC) was the largest for formulation B for all the evaluated flavonoid glycosides, however the differences were not statistically significant. It is concluded that the three formulations of Ginkgo biloba extract are bioequivalent.
科研通智能强力驱动
Strongly Powered by AbleSci AI